Skip to main content

Table 2 The Committee’s and the sample ranking of technologies evaluated by the 2006/7 Basket Committee (monthly cost threshold = 125 NIS)

From: Do the equity-efficiency preferences of the Israeli Basket Committee match those of Israeli health policy makers?

Technology Committee’s inclusion decision Rank Basket Committee Rank survey - Total Rank survey - Physicians Rank survey - Members of any Basket Committee Rank efficiencya
Crestor Ezetrol YES 1 18 18 15 12
Atacand Ocsaar Diovan Olmetec YES 2 29 29 25 3
Lantus Levemir YES 3 29 29 25 5
Apidra Humalog Novorapid YES 4 29 29 25 9
Eloxatin YES 5 15 15 15 4
Xeloda YES 6 15 15 15 1
Herceptin YES 7 11 11 12 23
Hepsera YES 8 3 3 3 16
Viread YES 9 9 8 7 22
Prevnar YES 10 33 33 33 32
Mabthera YES 11 1 1 1 14
Keppra YES 12 21 21 24 28
Zyprexa YES 13 22 22 22 6
Exjade YES 14 5 4 4 19
Plavix (cardiac) YES 15 8 8 5 10
Growth hormon YES 16 14 14 11 13
Plavix (stroke) YES 17 1 1 1 8
Velcade YES 18 4 5 5 27
Zomera NO 26.5 11 11 12 29
Apo-Go NO 26.5 6 6 9 21
Azilect NO 26.5 6 6 9 17
Cetuximab (Erbitux®) NO 26.5 25 24 25 31
Doxil NO 26.5 15 15 15 11
Emend NO 26.5 25 24 25 33
Erlotinib (Tarceva®) NO 26.5 25 24 25 30
Faslodex NO 26.5 11 11 12 24
Forteo NO 26.5 28 28 25 34
Gardasil NO 26.5 9 8 7 20
Lucentis NO 26.5 18 18 15 18
Rimonabant (Acomplia®) NO 26.5 34 34 34 25
Sifrol NO 26.5 20 20 21 26
Spiriva NO 26.5 29 29 25 7
Zemplar NO 26.5 22 22 22 15
Zyban NO 26.5 24 27 20 2
Mean rank YES 9.5 14.8 16.9 16.1 14.0
NO 26.5 19.3 19.2 18.8 21.4
  1. aBy international data on cost per QALY gained